ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®
Berlin, Germany and Bethesda, MD, USA, June 14, 2022 ProBioGen and ValenzaBio jointly announce today that they have entered into a second service agreement. The new project is a..
ValenzaBio Engages ProBioGen For a Second Service Project
Berlin, Germany and Bethesda, MD, USA, June 14, 2022 ProBioGen and ValenzaBio jointly announce today that they have entered into a second service agreement. The new project is a..
ProBioGen Grows by 50 Percent in Last Two Years
Susanne Kaestner and Thea Boehm Join Biopharma Company’s Team Berlin, Germany - June 2, 2022 The Berlin-based biopharmaceutical enterprise ProBioGen has increased its staff by 50..
Lutz Hilbrich Appointed as Senator to the Senate of Economy Europe
Berlin, Germany, March 7, 2022 MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy..
ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology
Berlin, Germany, March 7, 2022 MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy..
ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology
Berlin, Germany, February 11, 2022: ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology. Following evaluation of the..
ProBioGen announces Innovent as a new Partner signing License of GlymaxX® Technology
Berlin, Germany, January 11, 2022: ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology. Under..
Dr. Simon Bulling Joins ProBioGen as Chief Operating Officer to Drive Next Phase of Operational Growth
Apr 21, 2026
ProBioGen Introduces CMC Navigator™ to Help Biopharma Teams Select the Best CMC Path Forward
Feb 17, 2026
ProBioGen and Zag Bio™ Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy
Jan 6, 2026
ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101
Dec 9, 2025
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Oct 10, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-2.webp)
ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services
May 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
